First-Line Market For Melanoma Not A Lock For Bristol Or Roche
This article was originally published in The Pink Sheet Daily
Executive Summary
Data on Bristol's recently approved Yervoy and Roche's recently submitted vemurafenib show remarkable advances for melanoma but also establish competing options for first-line therapy.